Indication
ADHD
70 clinical trials
57 products
1 drug
Clinical trial
A Phase 3, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy and Safety Laboratory Classroom Study in Children (6-12) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)Status: Recruiting, Estimated PCD: 2024-01-01
Product
SerdexmethylphenidateProduct
CTx-1301Clinical trial
A Multicenter, Dose-Optimized, Open-Label, Safety/Tolerability and Pharmacokinetic Study With Azstarys® in Children 4 and 5 Years of Age With Attention-Deficit/Hyperactivity DisorderStatus: Recruiting, Estimated PCD: 2025-03-30
Product
Guanfacine hydrochlorideClinical trial
A Phase 4, Multicenter, 2-part Study Composed of a Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation Followed by a 1-Year Open-label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-release (SPD503) in Children and Adolescents Aged 6 to 17 Years With Attention-deficit/Hyperactivity DisorderStatus: Recruiting, Estimated PCD: 2027-06-28
Clinical trial
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multi-center, Fixed-dose, Parallel Group Efficacy and Safety in Pediatrics (6-17) With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)Status: Active (not recruiting), Estimated PCD: 2024-01-01
Product
AtomoxetineProduct
CTx-1301-DexmethylphenidateClinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD TreatmentStatus: Completed, Estimated PCD: 2019-09-04
Product
SPN-810Product
PlaceboClinical trial
A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHDStatus: Completed, Estimated PCD: 2013-03-01
Product
d-AmphetamineClinical trial
Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR in Adult Attention Deficit Hyperactivity DisorderStatus: Completed, Estimated PCD: 2024-01-17
Product
NRCT-101-SRClinical trial
Assessment of the Efficacy and Safety of Molindone Hydrochloride Extended-Release for the Treatment of Impulsive Aggression in Pediatric Patients With Attention Deficit/Hyperactivity Disorder in Conjunction With Standard ADHD TreatmentStatus: Completed, Estimated PCD: 2019-11-15
Product
MM-120Clinical trial
Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM-120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept TrialStatus: Completed, Estimated PCD: 2023-11-06
Product
Placebo patchProduct
SolriamfetolClinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Solriamfetol in AdultsStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Dose-Optimized, Randomized, Double Blind, Efficacy and Safety Study With Azstarys® in Children 4 to 12 Years of Age With Attention Deficit/Hyperactivity DisorderStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Zentiva®Clinical trial
Double-blind, Randomized, Parallel Group, Placebo Controlled Clinical Trial to Evaluate the Effects of Atomoxetine on Impulsivity in Behavioral Laboratory Tasks in Adult ADHD PatientsStatus: Recruiting, Estimated PCD: 2024-09-20
Clinical trial
A Two-Period Trial (Open-Label and Randomized Placebo-Controlled Substitution) of Droxidopa Treatment in Adults With ADHD With Co-administration of CarbidopaStatus: Completed, Estimated PCD: 2011-05-01
Product
AK0901Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Investigate the Efficacy, Safety and Tolerability of Oral Administered AK0901 Capsules in Children Aged 6-12 Years Old With Attention Deficit Hyperactivity DisorderStatus: Not yet recruiting, Estimated PCD: 2024-09-01
Product
Droxidopa+CarbidopaClinical trial
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine TreatmentStatus: Completed, Estimated PCD: 2016-07-01
Product
MethylphenidateProduct
CentanafadineClinical trial
A Randomized, Parallel, Double-Blind Efficacy and Safety Study of Biphentin Methylphenidate HCl Extended Release Capsules Compared to Placebo in Children and Adolescents 6 to 18 Years With Attention Deficit Hyperactivity Disorder (ADHD)Status: Completed, Estimated PCD: 2012-02-01
Clinical trial
A Pilot Phase 2a, Multicenter, Open-label, Single-dose Trial to Assess the Pharmacokinetics of Centanafadine Extended-release Capsules After Oral Administration in Pediatric Subjects (9 to 12 Years, Inclusive) With Attention-deficit Hyperactivity DisorderStatus: Completed, Estimated PCD: 2019-12-21
Clinical trial
An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity DisorderStatus: Completed, Estimated PCD: 2021-09-07
Clinical trial
Assessing the Frequency of Lidocaine Ineffectiveness in the General Population vs. Males With ADHD, and Females With ADHD, With or Without PMSStatus: Completed, Estimated PCD: 2020-03-01
Product
LidocaineClinical trial
A Randomized, Double-Blind Study of the Time Course of Response to Biphentin® Methylphenidate Hydrochloride ER Capsules Compared to Placebo in Children 6 to 12 Years With Attention Deficit Hyperactivity Disorder in Analog Classroom SettingStatus: Completed, Estimated PCD: 2011-06-18
Clinical trial
A Phase 3, Dose-Optimized, Randomized, Double-Blind, Placebo-Controlled, Single-Center, Parallel Efficacy and Safety Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Using CTx-1301 (Dexmethylphenidate)Status: Completed, Estimated PCD: 2023-06-13
Clinical trial
An Open-Label, Multicenter, Multiple-Dose, Safety and Tolerability Study of Adhansia XR® Extended-Release Capsules in Children 4 to 12 Years of AgeStatus: Terminated, Estimated PCD: 2022-04-27
Product
CannabisClinical trial
Treatment With Cannabis Oil Containing Canabidiol (CBD) Tetrahydrocannabinol (THC), Cannabidivarin (CBDV) or Cannabigerol (CBG) vs. Placebo of Persons Diagnosed With ADHD After Failure of Conventional TreatmentStatus: Terminated, Estimated PCD: 2022-12-31
Product
Adhansia XRProduct
Stimulant TherapyClinical trial
Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHDStatus: Completed, Estimated PCD: 2019-10-19
Product
AMPH ERProduct
OPDC-34712Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo Controlled Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Attention Deficit/ Hyperactivity DisorderStatus: Completed, Estimated PCD: 2011-06-20
Clinical trial
A Phase 3, Multicenter, Open-label, Long-term Trial Evaluating the Long-term Safety and Tolerability of Once Daily Centanafadine Capsules in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)Status: Recruiting, Estimated PCD: 2024-11-20
Clinical trial
Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHDStatus: Terminated, Estimated PCD: 2010-07-01
Product
StimulantsClinical trial
The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate DiscontinuationStatus: Completed, Estimated PCD: 2020-06-30
Product
OROS-MethylphenidateClinical trial
Acute Effects of Prescription Stimulant Medication on Cognition and Mood in College Students With and Without ADHDStatus: Recruiting, Estimated PCD: 2025-06-30
Product
Adderall IRClinical trial
Long Acting Stimulant Treatment of ADHD in Young ChildrenStatus: Completed, Estimated PCD: 2010-01-01
Product
methylphenidateClinical trial
A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder ComorbidityStatus: Completed, Estimated PCD: 2022-09-30
Clinical trial
2/2 Treating Mothers With ADHD and Their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation TrialStatus: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Efficacy of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum DisorderStatus: Recruiting, Estimated PCD: 2027-03-01
Product
AmphetamineProduct
Alpha 2 agonistClinical trial
Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Children and Adolescents With ADHDStatus: Withdrawn, Estimated PCD: 2028-12-01
Clinical trial
A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum DisorderStatus: Completed, Estimated PCD: 2023-03-31
Product
LisdexamfetamineClinical trial
Mindfulness-Based ADHD Treatment for Children: a Feasibility StudyStatus: Recruiting, Estimated PCD: 2024-06-30
Product
Goal-Standard MedicationClinical trial
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied DrugsStatus: Recruiting, Estimated PCD: 2024-05-01
Product
POP02Clinical trial
Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-PHNO PET in Healthy HumansStatus: Completed, Estimated PCD: 2023-01-17
Product
PHNOProduct
Dextro AmphetamineClinical trial
Relapse Prevention in Stimulant Use DisorderStatus: Withdrawn, Estimated PCD: 2025-01-11
Product
ContraveProduct
BupropionClinical trial
Solriamfetol for ADHD in Adults: A Double-Blind Placebo Controlled Pilot StudyStatus: Completed, Estimated PCD: 2023-01-27
Clinical trial
Evaluation of the Effectiveness of the FOCUS ADHD Mobile Health Platform in the Monitoring of Adults With Attention-Deficit/ Hyperactivity Disorder (ADHD)Status: Completed, Estimated PCD: 2022-09-30
Product
PsychostimulantClinical trial
The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With Attention Deficit Hyperactivity Disorder: A Lipidomic StudyStatus: Completed, Estimated PCD: 2021-01-25
Clinical trial
Open-Label Extension Study to Evaluate the Long-Term Safety of Molindone Hydrochloride Extended-Release Tablets for the Treatment of Impulsive Aggression in Pediatric and Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD TreatmentStatus: Terminated, Estimated PCD: 2021-05-01
Clinical trial
A Randomized Placebo-Controlled Trial of Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental DisordersStatus: Not yet recruiting, Estimated PCD: 2024-04-01
Product
SertralineClinical trial
Irritability in Children With ADHD and Emotion Dysregulation: Clinical Profiles, Neuropsychological Characteristics , and Pharmacological Treatment: A Cross-over StudyStatus: Completed, Estimated PCD: 2022-04-07
Clinical trial
An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate and Poor Metabolizers in Children With Attention Deficit/Hyperactivity DisorderStatus: Completed, Estimated PCD: 2022-06-01
Clinical trial
Dialectical Behavioral Therapy Skills for Impulsive Aggression in Children Diagnosed With Attention Deficit Hyperactivity Disorder at Alexandria University HospitalsStatus: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary ProteinStatus: Completed, Estimated PCD: 2014-06-01
Product
BP22042013Clinical trial
The Secret Trail of Moon (MOON): a Personalized Treatment Video Game for Children and Adolescents With ADHD Based on Cognitive Training and Self-regulationStatus: Completed, Estimated PCD: 2023-12-15
Product
Usual treatment for ADHDClinical trial
A Phase IV, Dose Optimized, Open Label, Evaluation of the Effect Foquest® (Methylphenidate HCl Controlled Release) on Sleep in Children Aged 6-12 With Attention Deficit Hyperactivity DisorderStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Product
FoquestClinical trial
Assessment of Efficacy and Safety of SPN-810 for the Treatment of Impulsive Aggression (IA) in Adolescent Subjects With Attention Deficit/Hyperactivity Disorder (ADHD) in Conjunction With Standard ADHD TreatmentStatus: Terminated, Estimated PCD: 2020-01-22
Drug
VarlilumabProduct
ConcertaProduct
Adderall-XRClinical trial
Neuroimaging Study of Risk Factors for Adolescent Bipolar DisorderStatus: Completed, Estimated PCD: 2022-08-01
Clinical trial
Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual DisabilitiesStatus: , Estimated PCD: 2025-09-29
Clinical trial
Evaluating Assessment and Medication Treatment of ADHD in Children With Down SyndromeStatus: Recruiting, Estimated PCD: 2025-09-30
Product
Quillivant XRClinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy and Safety of Once Daily Centanafadine Capsules for the Treatment of Children With Attention-deficit/Hyperactivity Disorder (ADHD)Status: Recruiting, Estimated PCD: 2025-10-30
Clinical trial
Objectifying the Day-time Response Variation of (Lis)Dexamphetamine in Adults With ADHDStatus: Completed, Estimated PCD: 2021-12-30
Product
Dexamfetamine SulfateProduct
Blood samplesClinical trial
Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 GeneStatus: Recruiting, Estimated PCD: 2024-08-01
Product
SulfonylureaClinical trial
Understanding the Mechanism of Action of Methylphenidate in ADHD: A Computational Psychiatry ApproachStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
COMT Inhibition as a Potential Therapeutic Target Among Individuals With Comorbid Alcohol Use Disorder and Attention-Deficit/Hyperactivity DisorderStatus: Recruiting, Estimated PCD: 2025-03-01
Product
TolcaponeClinical trial
Effect of Bifidobacterium Bifidum (Bf-688) on Clinical Characteristics and Gut Microbiota in Attention-deficit/Hyperactivity Disorder: a Double-blind Randomized-control TrialStatus: Completed, Estimated PCD: 2023-02-28
Clinical trial
Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use DisorderStatus: Completed, Estimated PCD: 2021-06-01
Clinical trial
Intervention for Teens With ADHD and Substance UseStatus: Terminated, Estimated PCD: 2021-08-01
Clinical trial
Evaluating the Efficacy of Supplementation With Micronutrients for ADHD in Youth (MADDY) StudyStatus: Completed, Estimated PCD: 2020-07-10
Clinical trial
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD RiskStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Methylphenidate and Response to Alcohol Cues (MARA) Pilot StudyStatus: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Neurophysiological Markers of Pediatric Irritability and Its Response to InterventionStatus: Recruiting, Estimated PCD: 2024-07-01
Product
CNS StimulantClinical trial
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHDStatus: , Estimated PCD: 2024-09-01
Clinical trial
Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity DisorderStatus: Completed, Estimated PCD: 2020-11-05
Product
OxytocinClinical trial
Phase 3, Multicenter, 3-Week Fixed-dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy, Safety and Pharmacokinetic Study of Evening Dosed Methylphenidate Hydrochloride Extended-Release Capsules (HLD200) in Children Aged 4 to 5 Years With ADHDStatus: Not yet recruiting, Estimated PCD: 2026-07-01
Product
Placebo HLD200